Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI™ platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. According to the company, the integrated platform combines PDAOAI™ with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing. This integration creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO).
“Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector,” the company stated in the press release. The advancement signals Oncotelic’s shift from a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products to also offering technology solutions for pharmaceutical manufacturing.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The completion of Phase 2 objectives is a significant milestone for Oncotelic, as it moves closer to offering a technology-enabled CDMO service that could streamline pharmaceutical manufacturing. The integration of AI and robotics in GMP manufacturing has the potential to improve efficiency, reduce errors, and lower costs for drug manufacturers. For the industry, this development represents a step toward more intelligent and automated production processes, which could accelerate the availability of sterile injectable drugs and other critical therapeutics. For investors and stakeholders, the platform’s commercialization may open new revenue streams through software licensing and partnerships, as detailed in the company’s announcements.
More information about Oncotelic Therapeutics is available at the company’s newsroom at https://nnw.fm/OTLC. The full press release can be viewed at https://nnw.fm/j1n43.
